Disclaimer: As of September 29, 2023, NeuroMend no longer offers Spravato treatments. We apologize for any inconvenience and encourage you to consult with our team or your healthcare provider for alternative options.
Effective immediately, the U.S. Food and Drug Administration has approved the use of Spravato (esketamine) nasal spray for the treatment of treatment-resistant depression, more commonly known as TRD.
